- 18 Downloads
In a retrospective observational single-centre study of 115 patients, conducted between July 2016 and July 2017, a patient [age and sex not stated] was described, who developed sleep disorder and mouth dryness during treatment with sofosbuvir/velpatasvir for hepatitis C. The patient, who had hepatitis C, started receiving sofosbuvir/velpatasvir [dosage and route not stated]. However, the patient developed sleep disorder and mouth dryness due to sofosbuvir/velpatasvir. Thereafter, the patient discontinued sofosbuvir/velpatasvir [duration of treatment to reactions onset and outcomes not stated].
Author comment: "[Sofosbuvir/velpatasvir] [patient] discontinued treatment. . . due to [adverse events]. . . sleep disorder and mouth dryness".
- Buggisch P, et al. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/ sofosbuvir hepatitis C treatment in a single centre in Germany. PLOS One 14: e0214795, No. 4, 2019. Available from: URL: http://doi.org/10.1371/journal.pone.0214795 - Germany